RxDoctor Payments Data

Elizabeth Allen

Primary Care · Bartlesville, OKNPI 1134909195

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $483 and has fallen 70.1% since, to $144 in 2025.

$657in general payments, 2019–2025

Across 32 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$122
  • Corium, LLC$121
  • Otsuka America Pharmaceutical, Inc.$121
  • Alkermes, Inc.$98
  • Vanda Pharmaceuticals Inc.$55
  • Almatica Pharma LLC$54
  • plus $86 from 4 others

What the payments were for

  • Food & beverage$657100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$657 in reported general payments places this provider in the 65th percentile of 83 primary care providers in Oklahoma.

See all primary care providers in Oklahoma

Medicare billing

Part B allowed, 2024
$23,435
Medicare patients
88
Services billed
13,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide74$113,733
OzempicSemaglutide66$80,239
TrulicityDulaglutide71$74,830
JardianceEmpagliflozin12$21,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$18,716
FarxigaDapagliflozin Propanediol12$12,356
Arnuity ElliptaFluticasone Furoate18$4,633
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,171
Gabapentin70$1,466
Omeprazole48$1,150
Albuterol Sulfate HfaAlbuterol Sulfate46$1,108
Ventolin HfaAlbuterol Sulfate13$1,102
Montelukast Sodium22$936
Duloxetine Hcl17$922
Fluticasone Propionate29$850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$21$188,563145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 83 primary care providers in Oklahoma.

Other primary care in Bartlesville

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →